The Technical Analyst
Select Language :
Medicenna Therapeutics [MDNA]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Medicenna Therapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals

Medicenna Therapeutics is listed at the  Exchange

-13.16% $0.157

America/New_York / 1 nov 2023 @ 16:00


Medicenna Therapeutics: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 10.93 mill
EPS: -0.0900
P/E: -1.744
Earnings Date: Nov 06, 2023
SharesOutstanding: 69.64 mill
Avg Daily Volume: 0.261 mill
RATING 2023-11-27
B
Neutral
RATINGS
Rating CashFlow: Strong Buy
Return On Equity: Sell
Return On Asset: Sell
DE: Sell
P/E: Sell
Price To Book: Neutral
QUARTER GROWTHS
2/223/224/221/232/233/23
Revenuen/an/an/an/an/an/a
Gr.Profitn/an/an/an/an/an/a
Ebit
Asset
Debtn/an/an/an/an/an/a
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -1.744 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.30x
Company: PE -1.744 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

$ 0.323 - 0.407

( +/- 11.51%)
ATR Model: 14 days

Forecast: 01:40 - $0.255

Live Trading Signals (every 1 min)

SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $0.157 (-13.16% )
Volume 1.256 mill
Avg. Vol. 0.261 mill
% of Avg. Vol 481.82 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Medicenna Therapeutics Corp.

Last 12 Months

Last 12 months chart data with high, low, open and close for Medicenna Therapeutics Corp.

RSI

Intraday RSI14 chart for Medicenna Therapeutics Corp.

Last 10 Buy & Sell Signals For MDNA

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Medicenna Therapeutics Corp.

MDNA

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.

Last 10 Buy Signals

Date Signal @
USDCUSDMar 29 - 05:48$1.000
ASTRUSDMar 29 - 05:440.138
KDAUSDMar 29 - 05:44$1.413
GLMRUSDMar 29 - 05:440.490
BATUSDMar 29 - 05:45$0.329
CTXCUSDMar 29 - 05:44$0.459
WOOUSDMar 29 - 05:43$0.453
SFPUSDMar 29 - 05:43$0.776
RPLUSDMar 29 - 05:43$31.06
ROUTEUSDMar 29 - 05:434.29

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.